SPECT: Clinical Trials

17 trials of SPECT, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 recruiting, 2 active not recruiting, 2 not yet recruiting. 17 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 117Completed 5, Recruiting 5, Active not recruiting 2, Not yet recruiting 2, Enrolling by invitation 1, Suspended 1, Withdrawn 1
Phase 23Recruiting 2, Completed 1

Follow SPECT: new trials by email Literature Review of SPECT trials Research Report on SPECT

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Phase 1Not yet recruitingNational Cancer Institute (NCI)302026-12-042026-06-12
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 1Not yet recruitingUniversity of Michigan Rogel Cancer Center202026-12-012026-10-15
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Phase 1WithdrawnNational Cancer Institute (NCI)2026-10-012026-08-28
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab - Refractory Myelodysplastic Syndrome
Phase 1SuspendedNational Cancer Institute (NCI)182026-09-032026-09-09
Molecular Imaging of EpCam Expression in Breast Cancer Using [99mTc]Tc-DARPinEc1-G3C
[99mTc]Tc-DARPinEc1-G3C - Primary Breast Cancer
Phase 1Enrolling by invitationTomsk National Research Medical Center of the Russian Academy of Sciences102026-06-222026-08-26
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1RecruitingCity of Hope Medical Center152025-07-012026-10-30
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Angiogram, Biospecimen Collection, Computed Tomography - Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
Phase 1 / Phase 2RecruitingJonsson Comprehensive Cancer Center252024-12-262026-08-21
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Phase 1RecruitingMayo Clinic212024-01-052026-07-01
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Phase 1Active not recruitingEmory University62023-11-292025-12-09
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
SPECT - Primary Breast Cancer
Phase 1CompletedTomsk National Research Medical Center of the Russian Academy of Sciences102023-09-012026-06-24
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2
SPECT - Breast Cancer Female
Phase 1CompletedTomsk National Research Medical Center of the Russian Academy of Sciences302021-12-222026-06-26
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
SPECT - Primary Breast Cancer
Phase 1CompletedTomsk National Research Medical Center of the Russian Academy of Sciences302020-02-102026-06-24
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center752017-10-242026-06-22
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm
Phase 1RecruitingMayo Clinic992017-04-042026-06-10
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1
Phase 1CompletedMayo Clinic92017-03-222024-09-27
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
Angiography, Computed Tomography, Planar Imaging - Metastatic Liver Carcinoma, Stage IV Liver Cancer
Phase 1Active not recruitingM.D. Anderson Cancer Center122017-01-092026-09-16
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Phase 1 / Phase 2CompletedMayo Clinic382004-10-012016-02-04

Conditions studied

Breast Neoplasms (4)  ·  Leukemia, Myeloid, Acute (3)  ·  Myelodysplastic Syndromes (3)  ·  Lymphoma, Large-Cell, Anaplastic (2)  ·  Lymphoma, T-Cell (2)  ·  Mycosis Fungoides (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Prostatic Neoplasms (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Immunoblastic Lymphadenopathy (1)

Sponsors

Mayo Clinic (4)  ·  Tomsk National Research Medical Center of the Russian Academy of Sciences (4)  ·  National Cancer Institute (NCI) (3)  ·  City of Hope Medical Center (1)  ·  Emory University (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  University of Michigan Rogel Cancer Center (1)

Countries

United States (11)  ·  Russia (4)

Top investigators

Armeen Mahvash (1)  ·  Brenda M. Sandmaier (1)  ·  David M Schuster, MD, FACR (1)  ·  Dusica Babovic-Vuksanovic, MD (1)  ·  Jeffrey Y Wong (1)  ·  Joselle Cook, M.B.B.S. (1)  ·  Kah Whye Peng, PhD (1)  ·  Kirk A Frey, MD (1)  ·  Megan Mantica (1)  ·  Nora Bennani, M.D. (1)  ·  Nora Bennani, MD (1)  ·  Olga Bragina, Dsc (1)  ·  Siddharth A Padia (1)  ·  Talha Badar (1)  ·  Thomas Witzig (1)

Results publications

PMID 35175355, PMID 30335787, PMID 33641042, PMID 34385343, PMID 36898933, PMID 38407630, PMID 41276366

NIH funding

P50CA186781 (2), R01CA262613 (2), P01CA078902 (1), P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA138292 (1), R01CA289631 (1), UM1CA186690 (1), UM1CA186709 (1), UM1CA186712 (1)